These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9514453

  • 1. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG.
    Am J Cardiol; 1998 Mar 01; 81(5):578-81. PubMed ID: 9514453
    [Abstract] [Full Text] [Related]

  • 2. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
    JAMA; 2001 Apr 04; 285(13):1711-8. PubMed ID: 11277825
    [Abstract] [Full Text] [Related]

  • 3. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T, MIRACL Study Investigators.
    Circulation; 2002 Sep 24; 106(13):1690-5. PubMed ID: 12270864
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
    Circulation; 2004 Jul 27; 110(4):386-91. PubMed ID: 15262833
    [Abstract] [Full Text] [Related]

  • 6. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA, Casciano R, Stern L, Rejas J.
    Eur J Health Econ; 2004 Oct 27; 5(3):278-84. PubMed ID: 15714350
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
    Ahsan CH, Shah A, Ezekowitz M.
    Curr Opin Cardiol; 2001 Nov 27; 16(6):390-3. PubMed ID: 11704711
    [Abstract] [Full Text] [Related]

  • 10. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP, Szucs TD.
    Med Klin (Munich); 2004 Sep 15; 99(9):500-5. PubMed ID: 15372179
    [Abstract] [Full Text] [Related]

  • 11. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A, Casciano R, Stern L, Svangren P.
    Int J Cardiol; 2004 Jul 15; 96(1):51-7. PubMed ID: 15203261
    [Abstract] [Full Text] [Related]

  • 12. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.
    Circulation; 2003 Sep 30; 108(13):1560-6. PubMed ID: 12975259
    [Abstract] [Full Text] [Related]

  • 13. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
    Olsson AG, Schwartz GG, Jonasson L, Linderfalk C.
    Acta Physiol Scand; 2002 Oct 30; 176(2):147-50. PubMed ID: 12354174
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Statins and unstable angina: MIRACL].
    Puel J.
    Ann Endocrinol (Paris); 2001 Feb 30; 62(1 Pt 2):145-8. PubMed ID: 11240417
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
    Correia LC, Spósito AC, Lima JC, Magalhães LP, Passos LC, Rocha MS, D'Oliveira A, Esteves JP.
    Am J Cardiol; 2003 Aug 01; 92(3):298-301. PubMed ID: 12888137
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA.
    Curr Atheroscler Rep; 2005 Mar 01; 7(2):85-6. PubMed ID: 15727720
    [No Abstract] [Full Text] [Related]

  • 20. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
    Waters DD, Hsue PY.
    Am J Cardiol; 2001 Oct 11; 88(7B):7J-16J. PubMed ID: 11595193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.